These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9697787)

  • 1. Inadequacy of free prostate-specific antigen parameters in the prediction of pathologic extent of prostate cancer in Japanese men.
    Egawa S; Suyama K; Soh S; Kuwao S; Uchida T; Koshiba K
    Urology; 1998 Aug; 52(2):230-6. PubMed ID: 9697787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer.
    Aslan G; Irer B; Kefi A; Celebi I; Yörükoğlu K; Esen A
    Int Urol Nephrol; 2005; 37(3):511-4. PubMed ID: 16307332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
    Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
    Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
    Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of extraprostatic extension in patients with clinically organ-confined prostate cancer.
    Lin S; Zhang Q; Li P; Li Z; Sun Y; Shao Y; Zhang X; Fu S
    Urol Int; 2014; 92(3):282-8. PubMed ID: 24280781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
    Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
    Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA.
    Grossklaus DJ; Smith JA; Shappell SB; Coffey CS; Chang SS; Cookson MS
    Urol Oncol; 2002; 7(5):195-8. PubMed ID: 12644216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men.
    Sokoll LJ; Mangold LA; Partin AW; Epstein JI; Bruzek DJ; Dunn W; Mohr P; Wallerson G; Chan DW
    Urology; 2002 Oct; 60(4 Suppl 1):18-23. PubMed ID: 12384158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of pathologic prostate-specific antigen mass ratio in patients with localized prostate cancer with negative surgical resection margins.
    Lee S; Jeong CW; Jeong SJ; Hong SK; Choi W; Byun SS; Lee SE
    Urology; 2013 Oct; 82(4):865-9. PubMed ID: 23830078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
    Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
    Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml.
    Zlotta AR; Djavan B; Petein M; Susani M; Marberger M; Schulman CC
    J Urol; 1998 Dec; 160(6 Pt 1):2089-95. PubMed ID: 9817330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer.
    Erdem E; Atsü N; Akbal C; Bilen CY; Ergen A; Ozen H
    Int Urol Nephrol; 2002; 34(4):519-23. PubMed ID: 14577496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer.
    Pannek J; Subong EN; Jones KA; Marschke PL; Epstein JI; Chan DW; Carter HB; Luderer AA; Partin AW
    Urology; 1996 Dec; 48(6A Suppl):51-4. PubMed ID: 8973700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early detection of prostate cancer in men with prostatism and intermediate prostate-specific antigen levels.
    Schmid HP; Ravery V; Billebaud T; Toublanc M; Boccon-Gibod LA; Hermieu JF; Delmas V; Boccon-Gibod L
    Urology; 1996 May; 47(5):699-703. PubMed ID: 8650868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy.
    Tombal B; Querton M; de Nayer P; Sauvage P; Cosyns JP; Feyaerts A; Opsomer R; Wese FX; Van Cangh PJ
    Urology; 2002 Feb; 59(2):256-60. PubMed ID: 11834398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.